Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4.77M | $4.76M | $5.92M | $7.31M | $9.68M | $10.1M | $0.00 | $1.43M | — | — |
| Revenue growth | — | -0.2% | 24.4% | 23.5% | 32.3% | 3.9% | -100.0% | — | — | — |
| Gross profit | $129K | $838K | $1.84M | $3.05M | $5.12M | $5.12M | $0.00 | $1.43M | — | — |
| Gross margin | 2.7% | 17.6% | 31.1% | 41.7% | 52.9% | 50.9% | — | 100.0% | — | — |
| Operating income | -$5.08M | -$6.31M | -$6.73M | -$5.25M | -$3.48M | -$3.45M | -$6.42M | -$40.9M | -$90.9M | -$114M |
| Operating margin | -106.6% | -132.5% | -113.6% | -71.8% | -35.9% | -34.3% | — | -2855.0% | — | — |
| Net income | -$4.71M | -$6.16M | -$6.70M | -$5.14M | -$3.45M | -$3.39M | -$7.27M | -$46.5M | -$79.3M | -$103M |
| Net margin | -98.8% | -129.4% | -113.1% | -70.3% | -35.6% | -33.7% | — | -3243.2% | — | — |
| EPS (diluted) | -$0.09 | -$0.11 | -$0.12 | -$0.08 | -$0.05 | -$0.03 | — | -$1.74 | -$1.23 | -$1.40 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$3.88M | -$5.71M | -$5.71M | -$5.05M | -$3.64M | -$2.84M | -$7.71M | -$36.9M | -$18.3M | -$82.5M |
| Capital expenditures | $479K | $549K | $337K | $444K | $273K | $381K | $266K | $1.07M | $54.4M | $12.7M |
| Free cash flow | -$4.36M | -$6.26M | -$6.05M | -$5.49M | -$3.91M | -$3.22M | -$7.98M | -$38.0M | -$72.7M | -$95.2M |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $10.1M | $5.93M | $2.60M | $5.33M | $2.39M | $63.8M | $55.9M | $9.24M | $61.6M | $30.6M |
| Total assets | $18.1M | $12.3M | $7.46M | $9.42M | $8.70M | $70.4M | $58.1M | $97.9M | $341M | $267M |
| Total liabilities | $1.70M | $1.67M | $2.42M | $1.74M | $2.98M | $3.01M | $3.45M | $22.7M | $50.4M | $59.9M |
| Long-term debt | — | — | — | — | — | — | — | $1.73M | $1.68M | $1.63M |
| Shareholders' equity | $16.4M | $10.6M | $5.03M | $7.68M | $5.72M | $67.4M | $54.6M | $75.2M | $291M | $207M |
| Retained earnings | -$66.4M | -$72.6M | -$79.3M | -$84.5M | -$87.9M | -$91.3M | -$106M | -$152M | -$232M | -$335M |
| Shares (wtd avg diluted) | 55.0M | 55.0M | 56.3M | 67.4M | 67.6M | 104M | 142M | 26.8M | 64.4M | 73.8M |
Every figure is extracted from Perspective Therapeutics, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.